Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is highlighted as one of the Best Beaten Down Growth Stocks to Buy According to Analysts. Truist Financial reiterated a Buy rating on HRMY following strong Q3 2025 WAKIX performance, generating $239 million in revenue and adding 500 patients to reach 8,100 average patients.

HRMY raised its revenue guidance for 2025 to $845 million – $865 million. The company develops and commercializes therapies for rare neurological diseases and unmet medical needs. While HRMY shows potential, some believe other AI stocks offer greater upside and less risk. For more information, check out the best short-term AI stock report.

Read more at Yahoo Finance: Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY)